Key Points
- Insider sale: Mark Sabag sold 62,102 TEVA shares on March 17 at an average $30.14 for about $1.87 million, trimming his stake by roughly 21.6% to 224,940 shares valued at ~$6.78 million.
- Fundamentals and analyst sentiment: Teva beat quarterly expectations with $0.96 EPS (vs. $0.65) and $4.71B revenue, set FY2026 guidance of 2.570–2.770 EPS, and enjoys mostly positive analyst coverage with a consensus target of $37.67 (Moderate Buy).
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the sale, the insider owned 224,940 shares in the company, valued at $6,779,691.60. This represents a 21.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Teva Pharmaceutical Industries Price Performance
Shares of TEVA stock opened at $29.42 on Friday. The company has a market capitalization of $33.83 billion, a PE ratio of 24.52, a price-to-earnings-growth ratio of 9.91 and a beta of 0.72. The firm has a fifty day simple moving average of $32.72 and a 200-day simple moving average of $26.94. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the previous year, the firm posted $0.71 EPS. The firm's quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 16th. Barclays raised their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an "overweight" rating in a research note on Friday, January 30th. Truist Financial upped their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a research report on Wednesday, February 18th. Bank of America increased their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, December 9th. Finally, The Goldman Sachs Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus target price of $37.67.
Check Out Our Latest Analysis on TEVA
Hedge Funds Weigh In On Teva Pharmaceutical Industries
Large investors have recently modified their holdings of the stock. Phoenix Financial Ltd. lifted its holdings in Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock worth $834,164,000 after acquiring an additional 3,533,800 shares during the last quarter. National Pension Service grew its holdings in shares of Teva Pharmaceutical Industries by 24.2% during the third quarter. National Pension Service now owns 2,073,293 shares of the company's stock valued at $41,881,000 after purchasing an additional 404,526 shares during the last quarter. Public Sector Pension Investment Board raised its position in shares of Teva Pharmaceutical Industries by 11.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company's stock worth $13,543,000 after purchasing an additional 69,000 shares during the period. Oak Harvest Investment Services acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company's stock worth $761,455,000 after purchasing an additional 4,306,363 shares during the last quarter. Institutional investors own 54.05% of the company's stock.
Key Headlines Impacting Teva Pharmaceutical Industries
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Brokerages set a new blended price target for TEVA at $37.67 — analyst coverage remains constructive and the target sits well above the current trading level, supporting upside expectations. Brokerages Set Teva Price Target at $37.67
- Positive Sentiment: Teva published its Q1 2026 Aide Memoire on the investor site — a summary of previously disclosed public information intended to orient investors ahead of results. This improves transparency and reduces surprise risk at earnings. Teva Releases Q1 2026 Aide Memoire
- Neutral Sentiment: Teva set the Q1 2026 results release for April 29 (press release at 7:00 a.m. ET; conference call/webcast at 8:00 a.m. ET). The scheduled cadence and webcast registration give investors a clear timeline to reprice around confirmed numbers. Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results
- Negative Sentiment: Insider selling: Mark Sabag sold 62,102 TEVA shares on March 17 at an average $30.14, reducing his stake ~21.6% — notable executive selling can weigh on sentiment and be interpreted as a near-term negative by some investors. Insider Sale Disclosure — Mark Sabag
Teva Pharmaceutical Industries Company Profile
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
